How AI can help us count the ‘good’ viruses used in biopharmaceuticals
Peer-Reviewed Publication
Updates every hour. Last Updated: 23-Jun-2026 05:16 ET (23-Jun-2026 09:16 GMT/UTC)
Researchers have developed a new methodology that uses artificial intelligence (AI) tools to identify and count target viruses more efficiently than previous techniques. The new approach can be used in applications such as pharmaceutical biomanufacturing.
Over the years, scientific research has led to the development of several pharmacological therapies for this disease. Now, a study coordinated by the University of Trento (Italy) marks a turning point, as it identified a gene therapy for individuals with cystic fibrosis caused by a specific mutation and for whom there was no treatment available until now. They are about 10% of all those with the disease. The results open up further prospects because they could lead to a definitive cure for patients with cystic fibrosis who are currently dependent on drugs.
For centuries, the inability to regrow lost body parts has been considered a defining limitation of humans and other mammals. While animals like salamanders can regenerate entire limbs, humans are left with scar tissue.
But new research from the Texas A&M College of Veterinary Medicine and Biomedical Sciences (VMBS) suggests that this limitation may not be permanent. Instead, the capacity for regeneration may still exist — hidden within the body’s normal healing process.
A new ultra-efficient microchip developed at MIT enables resource-constrained wireless biomedical devices to implement post-quantum encryption protocols that can defend against cyberattacks from powerful quantum computers.
New research using data from the Canadian Longitudinal Study on Aging (CLSA) reveals that employment stability and in-person work buffered older adults against depression during the first year of COVID-19.